---
title: 'Cannabidiol for treatment of irritability and aggressive behavior in children
  and adolescents with autism spectrum disorder: background and methods of the cannabidiol
  study in children with autism spectrum disorder study.**DOI:** 10.18203/2349-3259.ijct20250131'
authors:
- Elise MSannar
- JoanWinter
- Ronda KFranke
- EmilyWerner
- RebeccaRochowiak
- Patrick WRomani
- Owen SMiller
- NicoleSemmler
- Jacquelyn LBainbridge
- CrystalNatvig
- Susan KMikulich-Gilbertson
- Nicole RTartaglia
journal: International journal of clinical trials
doi: 10.18203/2349-3259.ijct20250131
publication_date: ''
source: Processed from scraped content
processing_date: '2025-10-21T22:15:01.443817'
content_type: research_paper
conditions:
- tourette_syndrome
- asd
- related_disorders
topics: []
categories:
- tourette
- asd
- related-disorders
reading_level: academic
audience:
- professional
- researcher
patient_friendly: false
search_priority: standard
keywords:
- clinical
- behavioral
- children
- trial
- adolescents
- treatment
search_tags:
- asd
- related_disorders
- peer-reviewed
- tourette_syndrome
- academic
- research
---

# Cannabidiol for treatment of irritability and aggressive behavior in children and adolescents with autism spectrum disorder: background and methods of the cannabidiol study in children with autism spectrum disorder study.**DOI:** 10.18203/2349-3259.ijct20250131

**Authors:** Elise MSannar, JoanWinter, Ronda KFranke, EmilyWerner, RebeccaRochowiak, Patrick WRomani, Owen SMiller, NicoleSemmler, Jacquelyn LBainbridge, CrystalNatvig, Susan KMikulich-Gilbertson, Nicole RTartaglia

**Journal:** International journal of clinical trials

**DOI:** 10.18203/2349-3259.ijct20250131

## Abstract

Autism spectrum disorder (ASD) is a neurodevelopmental disorder commonly associated with behavioral challenges. There are few evidence based pharmacological interventions available for the treatment of behavioral symptoms associated with ASD. Cannabidiol (CBD), the non-intoxicating component of cannabis, has known neuroprotective, antiepileptic, anxiolytic, and antipsychotic effects and may be useful in treating the behavioral symptoms of ASD.
We describe the research methods of a 27-week randomized placebo-controlled crossover trial to evaluate the safety and efficacy of oral CBD for the treatment of irritability and aggression associated with ASD, as measured by the irritability subscale of the aberrant behavior checklist-2
There is significant need for clinical research exploring alternative medications for the treatment of behavioral symptoms of ASD. Upcoming results from this trial will help answer the question of whether CBD may be a useful intervention in the management of ASD.
NCT04520685.

We describe the research methods of a 27-week randomized placebo-controlled crossover trial to evaluate the safety and efficacy of oral CBD for the treatment of irritability and aggression associated with ASD, as measured by the irritability subscale of the aberrant behavior checklist-2
There is significant need for clinical research exploring alternative medications for the treatment of behavioral symptoms of ASD. Upcoming results from this trial will help answer the question of whether CBD may be a useful intervention in the management of ASD.
NCT04520685.## Full Text## Abstract
background: autism spectrum disorder (asd) is a neurodevelopmental disorder commonly associated with behavioral challenges. there are few evidence based pharmacological interventions available for the treatment of behavioral symptoms associated with asd. cannabidiol (cbd), the non-intoxicating component of cannabis, has known neuroprotective, antiepileptic, anxiolytic, and antipsychotic effects and may be useful in treating the behavioral symptoms of asd. methods: we describe the research methods of a 27-week randomized placebo-controlled crossover trial to evaluate the safety and efficacy of oral cbd for the treatment of irritability and aggression associated with asd, as measured by the irritability subscale of the aberrant behavior checklist-2 nd edition (abc-2) in children and adolescents. conclusions: there is significant need for clinical research exploring alternative medications for the treatment of behavioral symptoms of asd. upcoming results from this trial will help answer the question of whether cbd may be a useful intervention in the management of asd. clinical trial registry: nct04520685. metrics metrics loading ... window.onload = function () { var options = { paperbuzzstatsjson: json.parse('{\"altmetrics_sources\":[{\"events\":null,\"events_count\":265,\"events_count_by_day\":[{\"count\":1,\"date\":\"2025-01-28\"},{\"count\":4,\"date\":\"2025-01-29\"},{\"count\":3,\"date\":\"2025-02-01\"},{\"count\":2,\"date\":\"2025-02-02\"},{\"count\":3,\"date\":\"2025-02-03\"},{\"count\":2,\"date\":\"2025-02-04\"},{\"count\":2,\"date\":\"2025-02-05\"},{\"count\":1,\"date\":\"2025-02-07\"},{\"count\":1,\"date\":\"2025-02-08\"},{\"count\":1,\"date\":\"2025-02-10\"},{\"count\":1,\"date\":\"2025-02-11\"},{\"count\":2,\"date\":\"2025-02-12\"},{\"count\":1,\"date\":\"2025-02-14\"},{\"count\":1,\"date\":\"2025-02-17\"},{\"count\":3,\"date\":\"2025-02-18\"},{\"count\":1,\"date\":\"2025-02-19\"},{\"count\":6,\"date\":\"2025-02-20\"},{\"count\":2,\"date\":\"2025-02-21\"},{\"count\":1,\"date\":\"2025-02-22\"},{\"count\":1,\"date\":\"2025-02-23\"},{\"count\":1,\"date\":\"2025-02-24\"},{\"count\":2,\"date\":\"2025-02-25\"},{\"count\":6,\"date\":\"2025-02-26\"}],\"events_count_by_month\":[{\"count\":5,\"date\":\"2025-01\"},{\"count\":45,\"date\":\"2025-02\"},{\"count\":32,\"date\":\"2025-03\"},{\"count\":37,\"date\":\"2025-04\"},{\"count\":26,\"date\":\"2025-05\"},{\"count\":23,\"date\":\"2025-06\"},{\"count\":19,\"date\":\"2025-07\"},{\"count\":24,\"date\":\"2025-08\"},{\"count\":24,\"date\":\"2025-09\"},{\"count\":30,\"date\":\"2025-10\"}],\"events_count_by_year\":[{\"count\":265,\"date\":null}],\"source\":{\"display_name\":\"pdf views\"},\"source_id\":\"pdf\"}]}'), minitemstoshowgraph: { mineventsforyearly: 10, mineventsformonthly: 10, mineventsfordaily: 6, minyearsforyearly: 3, minmonthsformonthly: 2, mindaysfordaily: 1 //first 30 days only }, graphheight: 150, graphwidth: 300, showtitle: false, showmini: false, published_date: [2025, 1, 28], } var paperbuzzviz = undefined; paperbuzzviz = new paperbuzzviz(options); paperbuzzviz.initviz(); } references american psychiatric association. diagnostic and statistical manual of mental disorders (5th ed.). washington, dc, usa: american psychiatric publishing. 2013. doi: https://doi.org/10.1176/appi.books.9780890425596 fombonne e, croen la, bulkley je, varga am, daida yg, hatch ba, et al. emotional and behavioral problems in youth with autism: high prevalence and impact on functioning. j dev behav pediatr. 2022;43(3):140-8. doi: https://doi.org/10.1097/dbp.0000000000001028 maenner mj, warren z, williams ar, amoakohene e, bakian av, bilder da, et al. prevalence and characteristics of autism spectrum disorder among children aged 8 years-autism and developmental disabilities monitoring network, 11 sites, united states, 2020. mmwr surveill summ. 2023;72(2):1-14. doi: https://doi.org/10.15585/mmwr.ss7202a1 owen r, sikich l, marcus rn, corey-lisle p, manos g, mcquade rd, et al. aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. pediatrics. 2009;124(6):1533-40. doi: https://doi.org/10.1542/peds.2008-3782 mccracken jt, mcgough j, shah b, cronin p, hong d, aman mg, et al. research units on pediatric psychopharmacology autism network. risperidone in children with autism and serious behavioral problems. n engl j med. 2002;347(5):314-21. doi: https://doi.org/10.1056/nejmoa013171 jobski k, höfer j, hoffmann f, bachmann c. use of psychotropic drugs in patients with autism spectrum disorders: a systematic review. acta psychiatr scand. 2017;135(1):8-28. doi: https://doi.org/10.1111/acps.12644 zou m, li d, li l, wu l, sun c. role of the endocannabinoid system in neurological disorders. int j dev neurosci. 2019;76:95-102. doi: https://doi.org/10.1016/j.ijdevneu.2019.03.002 campos ac, fogaça mv, scarante ff, joca srl, sales aj, gomes fv, et al. plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders. front pharmacol. 2017;8:269. doi: https://doi.org/10.3389/fphar.2017.00269 zamberletti e, gabaglio m, parolaro d. the endocannabinoid system and autism spectrum disorders: insights from animal models. int j mol sci. 2017;18(9):1916. doi: https://doi.org/10.3390/ijms18091916 silva junior ead, medeiros wmb, dos santos jpm, de sousa jmm, da costa fb, pontes km, et al. evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. trends psychiatry psychother. 2024;46:e20210396. doi: https://doi.org/10.47626/2237-6089-2021-0396 montagner pss, medeiros w, da silva lcr, borges cn, brasil-neto j, de deus silva barbosa v, et al. individually tailored dosage regimen of full-spectrum cannabis extracts for autistic core and comorbid symptoms: a real-life report of multi-symptomatic benefits. front psychiatry. 2023;14:1210155. doi: https://doi.org/10.3389/fpsyt.2023.1210155 schnapp a, harel m, cayam-rand d, cassuto h, polyansky l, aran a. a placebo-controlled trial of cannabinoid treatment for disruptive behavior in children and adolescents with autism spectrum disorder: effects on sleep parameters as measured by the cshq. biomedicines. 2022;10(7):1685. doi: https://doi.org/10.3390/biomedicines10071685 stolar o, hazan a, vissoker re, kishk ia, barchel d, lezinger m, et al. medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: an interim analysis of biochemical safety. front pharmacol. 2022;13:977484. doi: https://doi.org/10.3389/fphar.2022.977484 krebs mo, kebir o, jay tm. exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders. eur j pain. 2019;23(7):1225-1233. doi: https://doi.org/10.1002/ejp.1377 berry-kravis e, hagerman r, budimirovic d, erickson c, heussler h, tartaglia n, et al. a randomized, controlled trial of zyn002 cannabidiol transdermal gel in children and adolescents with fragile x syndrome (connect-fx). j neurodev disord. 2022;14(1):56. doi: https://doi.org/10.1186/s11689-022-09466-6 epidiolex ® (package insert). carlsbad, ca, usa: greenwich biosciences inc. 2018. thiele ea, marsh ed, french ja, mazurkiewicz-beldzinska m, benbadis sr, joshi c, et al. gwpcare4 study group. cannabidiol in patients with seizures associated with lennox-gastaut syndrome (gwpcare4): a randomised, double-blind, placebo-controlled phase 3 trial. lancet. 2018;391(10125):1085-96. doi: https://doi.org/10.1016/s0140-6736(18)30136-3 devinsky o, cross jh, laux l, marsh e, miller i, nabbout r, et al. cannabidiol in dravet syndrome study group. trial of cannabidiol for drug-resistant seizures in the dravet syndrome. n engl j med. 2017;376(21):2011-20. doi: https://doi.org/10.1056/nejmoa1611618 thiele ea, bebin em, bhathal h, jansen fe, kotulska k, lawson ja, et al. gwpcare6 study group. add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial. jama neurol. 2021;78(3):285-92. doi: https://doi.org/10.1001/jamaneurol.2020.4607 aman mg, singh nn. aberrant behavior checklist-2nd edition (abc-2). east aurora, ny, usa: slosson educational publications, inc. 1985. doi: https://doi.org/10.1037/t10453-000 roid hg, pomplun m. the stanford-binet intelligence scales. new york, ny, usa: the guilford press. 2012. sparrow ss, balla da, cicchetti dv. vineland adaptive behavior scales-third edition. san antonio, tx, usa: pearson. 2016. esbensen aj, rojahn j, aman mg, ruedrich s. anxiety, depression and mood scale (adams). columbus, ohio, usa: nisonger center. 2003. doi: https://doi.org/10.1037/t10454-000 butter e, mulick j. the ohio autism clinical impressions scale (oacis). columbus, oh, usa: children's research institute. 2006. constantino j. (srs™) social responsiveness scale-second edition. torrance, ca, usa: western psychological services. 2012. krug d, arick j, almond p. autism screening instrument for educational planning-third edition. austin, tx, usa: proed. 2008. bodfish jw, symons fw, parker de, lewis mh. the repetitive behavior scale-revised. dubuque, ia, usa: apa psyc tests. 2000. doi: https://doi.org/10.1037/t17338-000 malow ba, connolly hv, weiss sk, halbower a, goldman s, hyman sl, et al. the pediatric sleep clinical global impressions scale-a new tool to measure pediatric insomnia in autism spectrum disorders. j dev behav pediatr. 2016;37(5):370-6. doi: https://doi.org/10.1097/dbp.0000000000000307 gioia ga, isquith pk, guy sc, kenworthy l. behavior rating inventory of executive function®, second edition (brief®2). lutz, fl, usa: par inc. 2015. doi: https://doi.org/10.1037/t79467-000 leadbitter k, aldred c, mcconachie h, le couteur a, kapadia d, charman t, et al. pact consortium. the autism family experience questionnaire (afeq): an ecologically-valid, parent-nominated measure of family experience, quality of life and prioritised outcomes for early intervention. j autism dev disord. 2018;48(4):1052-62. doi: https://doi.org/10.1007/s10803-017-3350-7 forrest cb, ravens-sieberer u, devine j, becker bd, teneralli r, moon j, et al. development and evaluation of the promis® pediatric positive affect item bank, child-report and parent-proxy editions. j happiness stud. 2018;19(3):699-718. doi: https://doi.org/10.1007/s10902-016-9843-9 salsman jm, lai js, hendrie hc, butt z, zill n, pilkonis pa, et al. assessing psychological well-being: self-report instruments for the nih toolbox. qual life res. 2014;23(1):205-15. doi: https://doi.org/10.1007/s11136-013-0452-3 varni jw. the pedsql. san diego, ca, usa: children’s hospital and health center. 1999. posner k, brent d, lucas c, gould m, stanley b, brown g, et al. columbia suicide severity scale (c-ssrs). new york, ny, usa: the research foundation for mental hygiene. 2008. curran hv, freeman tp, mokrysz c, lewis da, morgan cj, parsons lh. keep off the grass? cannabis, cognition and addiction. nat rev neurosci. 2016;17(5):293-306. doi: https://doi.org/10.1038/nrn.2016.28 aran a, cayam rand d. cannabinoid treatment for the symptoms of autism spectrum disorder. expert opin emerg drugs. 2024;29(1):65-79. doi: https://doi.org/10.1080/14728214.2024.2306290 downloads pdf published 2025-01-28 how to cite sannar, e. m., winter, j., franke, r. k., werner, e., rochowiak, r., romani, p. w., miller, o. s., semmler, n., bainbridge, j. l., natvig, c., mikluich-gilbertson, s. k., & tartaglia, n. r. (2025). cannabidiol for treatment of irritability and aggressive behavior in children and adolescents with autism spectrum disorder: background and methods of the cannabidiol study in children with autism spectrum disorder study. international journal of clinical trials , 12 (1), 29–37. https://doi.org/10.18203/2349-3259.ijct20250131 more citation formats acm acs apa abnt chicago harvard ieee mla turabian vancouver download citation endnote/zotero/mendeley (ris) bibtex issue vol. 12 no. 1 (2025): january-march 2025 section protocols make a submission make a submission information for readers for authors for librarians keywords function randomcolor() { var cores = ['#1f77b4', '#ff7f0e', '#2ca02c', '#d62728', '#9467bd', '#8c564b', '#e377c2', '#7f7f7f', '#bcbd22', '#17becf']; return cores[math.floor(math.random()*cores.length)]; } document.addeventlistener("domcontentloaded", function() { var keywords = [{"text":"clinical trials","size":26},{"text":"clinical trial","size":17},{"text":"pain","size":9},{"text":"risk based monitoring","size":8},{"text":"clinical research","size":8},{"text":"physical activity","size":8},{"text":"covid-19","size":8},{"text":"india","size":8},{"text":"fentanyl","size":8},{"text":"ropivacaine","size":6},{"text":"anxiety","size":6},{"text":"randomized controlled trial","size":6},{"text":"depression","size":6},{"text":"osteoarthritis","size":5},{"text":"stroke","size":5},{"text":"obesity","size":5},{"text":"safety","size":5},{"text":"nutrition","size":5},{"text":"diabetes","size":5},{"text":"protocol","size":5},{"text":"type 2 diabetes mellitus","size":5},{"text":"dexmedetomidine","size":5},{"text":"physiotherapy","size":5},{"text":"oncology","size":5},{"text":"cancer","size":4},{"text":"randomized clinical trials","size":4},{"text":"efficacy","size":4},{"text":"quality of life","size":4},{"text":"children","size":4},{"text":"blood pressure","size":4},{"text":"bupivacaine","size":4},{"text":"exercise","size":4},{"text":"adolescents","size":4},{"text":"chemotherapy","size":3},{"text":"vitamin k2","size":3},{"text":"ctri","size":3},{"text":"nicotine","size":3},{"text":"e-cigarette","size":3},{"text":"hiv","size":3},{"text":"hysterosalpingography","size":3},{"text":"epilepsy","size":3},{"text":"cardiovascular disease","size":3},{"text":"iron deficiency anemia","size":3},{"text":"patents","size":3},{"text":"primary care","size":3},{"text":"ischemic stroke","size":3},{"text":"pharmacokinetics","size":3},{"text":"thrombocytopenia","size":3},{"text":"smartphone","size":3},{"text":"good clinical practice","size":3}]; var totalweight = 0; var width = 300; var height = 200; var transitionduration = 200; var length_keywords = keywords.length; var layout = d3.layout.cloud(); layout.size([width, height]) .words(keywords) .fontsize(function(d) { return fontsize(+d.size); }) .on('end', draw); var svg = d3.select("#wordcloud").append("svg") .attr("viewbox", "0 0 " + width + " " + height) .attr("width", '100%'); function update() { var words = layout.words(); fontsize = d3.scalelinear().range([16, 34]); if (words.length) { fontsize.domain([+words[words.length - 1].size || 1, +words[0].size]); } } keywords.foreach(function(item,index){totalweight += item.size;}); update(); function draw(words, bounds) { var w = layout.size()[0], h = layout.size()[1]; scaling = bounds ? math.min( w / math.abs(bounds[1].x - w / 2), w / math.abs(bounds[0].x - w / 2), h / math.abs(bounds[1].y - h / 2), h / math.abs(bounds[0].y - h / 2), ) / 2 : 1; svg .append("g") .attr( "transform", "translate(" + [w >> 1, h >> 1] + ")scale(" + scaling + ")", ) .selectall("text") .data(words) .enter().append("text") .style("font-size", function(d) { return d.size + "px"; }) .style("font-family", 'serif') .style("fill", randomcolor) .style('cursor', 'pointer') .style('opacity', 0.7) .attr('class', 'keyword') .attr("text-anchor", "middle") .attr("transform", function(d) { return "translate(" + [d.x, d.y] + ")rotate(" + d.rotate + ")"; }) .text(function(d) { return d.text; }) .on("click", function(d, i){ window.location = "https://www.ijclinicaltrials.com/index.php/ijct/search?query=query_slug".replace(/query_slug/, encodeuricomponent(''+d.text+'')); }) .on("mouseover", function(d, i) { d3.select(this).transition() .duration(transitionduration) .style('font-size',function(d) { return (d.size + 3) + "px"; }) .style('opacity', 1); }) .on("mouseout", function(d, i) { d3.select(this).transition() .duration(transitionduration) .style('font-size',function(d) { return d.size + "px"; }) .style('opacity', 0.7); }) .on('resize', function() { update() }); } layout.start(); }); current issue international journal of clinical trials. copyright © 2025. print issn: 2349-3240 | online issn: 2349-3259 editor@ijclinicaltrials.com , medipeditor@gmail.com (function (w, d, s, l, i) { w[l] = w[l] || []; var f = d.getelementsbytagname(s)[0], j = d.createelement(s), dl = l != 'datalayer' ? '&l=' + l : ''; j.async = true; j.src = 'https://www.googletagmanager.com/gtag/js?id=' + i + dl; f.parentnode.insertbefore(j, f); function gtag(){datalayer.push(arguments)}; gtag('js', new date()); gtag('config', i); }) (window, document, 'script', 'datalayer', 'ua-130662560-4');## Introduction
and methods of the cannabidiol study in children with autism spectrum disorder study | international journal of clinical trials skip to main content skip to main navigation menu skip to site footer open menu international journal of clinical trials home about about the journal submissions editorial team privacy statement contact login register articles in press current archives author guidelines search home / archives / vol. 12 no. 1 (2025): january-march 2025 / protocols cannabidiol for treatment of irritability and aggressive behavior in children and adolescents with autism spectrum disorder: background and methods of the cannabidiol study in children with autism spectrum disorder study authors elise m. sannar pediatric mental health institute, children’s hospital colorado, aurora, colorado, usa joan winter pediatric mental health institute, children’s hospital colorado, aurora, colorado, usa ronda k. franke department of pediatrics, children’s hospital colorado, aurora, colorado, usa emily werner department of pediatrics, children’s hospital colorado, aurora, colorado, usa rebecca rochowiak neuroscience institute, children’s hospital colorado, aurora, colorado, usa patrick w. romani pediatric mental health institute, children’s hospital colorado, aurora, colorado, usa owen s. miller department of clinical pharmacy, skaggs school of pharmacy, aurora, colorado, usa nicole semmler department of clinical pharmacy, skaggs school of pharmacy, aurora, colorado, usa jacquelyn l. bainbridge department of clinical pharmacy, skaggs school of pharmacy, aurora, colorado, usa crystal natvig department of psychiatry, university of colorado school of medicine, aurora, colorado, usa susan k. mikluich-gilbertson department of psychiatry, university of colorado school of medicine, aurora, colorado, usa nicole r. tartaglia department of pediatrics, children’s hospital colorado, aurora, colorado, usa doi: https://doi.org/10.18203/2349-3259.ijct20250131 keywords: autism spectrum disorder, cannabidiol, medication, clinical trial abstract background: autism spectrum disorder (asd) is a neurodevelopmental disorder commonly associated with behavioral challenges. there are few evidence based pharmacological interventions available for the treatment of behavioral symptoms associated with asd. cannabidiol (cbd), the non-intoxicating component of cannabis, has known neuroprotective, antiepileptic, anxiolytic, and antipsychotic effects and may be useful in treating the behavioral symptoms of asd. methods: we describe the research methods of a 27-week randomized placebo-controlled crossover trial to evaluate the safety and efficacy of oral cbd for the treatment of irritability and aggression associated with asd, as measured by the irritability subscale of the aberrant behavior checklist-2 nd edition (abc-2) in children and adolescents. conclusions: there is significant need for clinical research exploring alternative medications for the treatment of behavioral symptoms of asd. upcoming results from this trial will help answer the question of whether cbd may be a useful intervention in the management of asd. clinical trial registry: nct04520685. metrics metrics loading ... window.onload = function () { var options = { paperbuzzstatsjson: json.parse('{\"altmetrics_sources\":[{\"events\":null,\"events_count\":265,\"events_count_by_day\":[{\"count\":1,\"date\":\"2025-01-28\"},{\"count\":4,\"date\":\"2025-01-29\"},{\"count\":3,\"date\":\"2025-02-01\"},{\"count\":2,\"date\":\"2025-02-02\"},{\"count\":3,\"date\":\"2025-02-03\"},{\"count\":2,\"date\":\"2025-02-04\"},{\"count\":2,\"date\":\"2025-02-05\"},{\"count\":1,\"date\":\"2025-02-07\"},{\"count\":1,\"date\":\"2025-02-08\"},{\"count\":1,\"date\":\"2025-02-10\"},{\"count\":1,\"date\":\"2025-02-11\"},{\"count\":2,\"date\":\"2025-02-12\"},{\"count\":1,\"date\":\"2025-02-14\"},{\"count\":1,\"date\":\"2025-02-17\"},{\"count\":3,\"date\":\"2025-02-18\"},{\"count\":1,\"date\":\"2025-02-19\"},{\"count\":6,\"date\":\"2025-02-20\"},{\"count\":2,\"date\":\"2025-02-21\"},{\"count\":1,\"date\":\"2025-02-22\"},{\"count\":1,\"date\":\"2025-02-23\"},{\"count\":1,\"date\":\"2025-02-24\"},{\"count\":2,\"date\":\"2025-02-25\"},{\"count\":6,\"date\":\"2025-02-26\"}],\"events_count_by_month\":[{\"count\":5,\"date\":\"2025-01\"},{\"count\":45,\"date\":\"2025-02\"},{\"count\":32,\"date\":\"2025-03\"},{\"count\":37,\"date\":\"2025-04\"},{\"count\":26,\"date\":\"2025-05\"},{\"count\":23,\"date\":\"2025-06\"},{\"count\":19,\"date\":\"2025-07\"},{\"count\":24,\"date\":\"2025-08\"},{\"count\":24,\"date\":\"2025-09\"},{\"count\":30,\"date\":\"2025-10\"}],\"events_count_by_year\":[{\"count\":265,\"date\":null}],\"source\":{\"display_name\":\"pdf views\"},\"source_id\":\"pdf\"}]}'), minitemstoshowgraph: { mineventsforyearly: 10, mineventsformonthly: 10, mineventsfordaily: 6, minyearsforyearly: 3, minmonthsformonthly: 2, mindaysfordaily: 1 //first 30 days only }, graphheight: 150, graphwidth: 300, showtitle: false, showmini: false, published_date: [2025, 1, 28], } var paperbuzzviz = undefined; paperbuzzviz = new paperbuzzviz(options); paperbuzzviz.initviz(); } references american psychiatric association. diagnostic and statistical manual of mental disorders (5th ed.). washington, dc, usa: american psychiatric publishing. 2013. doi: https://doi.org/10.1176/appi.books.9780890425596 fombonne e, croen la, bulkley je, varga am, daida yg, hatch ba, et al. emotional and behavioral problems in youth with autism: high prevalence and impact on functioning. j dev behav pediatr. 2022;43(3):140-8. doi: https://doi.org/10.1097/dbp.0000000000001028 maenner mj, warren z, williams ar, amoakohene e, bakian av, bilder da, et al. prevalence and characteristics of autism spectrum disorder among children aged 8 years-autism and developmental disabilities monitoring network, 11 sites, united states, 2020. mmwr surveill summ. 2023;72(2):1-14. doi: https://doi.org/10.15585/mmwr.ss7202a1 owen r, sikich l, marcus rn, corey-lisle p, manos g, mcquade rd, et al. aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. pediatrics. 2009;124(6):1533-40. doi: https://doi.org/10.1542/peds.2008-3782 mccracken jt, mcgough j, shah b, cronin p, hong d, aman mg, et al. research units on pediatric psychopharmacology autism network. risperidone in children with autism and serious behavioral problems. n engl j med. 2002;347(5):314-21. doi: https://doi.org/10.1056/nejmoa013171 jobski k, höfer j, hoffmann f, bachmann c. use of psychotropic drugs in patients with autism spectrum disorders: a systematic review. acta psychiatr scand. 2017;135(1):8-28. doi: https://doi.org/10.1111/acps.12644 zou m, li d, li l, wu l, sun c. role of the endocannabinoid system in neurological disorders. int j dev neurosci. 2019;76:95-102. doi: https://doi.org/10.1016/j.ijdevneu.2019.03.002 campos ac, fogaça mv, scarante ff, joca srl, sales aj, gomes fv, et al. plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders. front pharmacol. 2017;8:269. doi: https://doi.org/10.3389/fphar.2017.00269 zamberletti e, gabaglio m, parolaro d. the endocannabinoid system and autism spectrum disorders: insights from animal models. int j mol sci. 2017;18(9):1916. doi: https://doi.org/10.3390/ijms18091916 silva junior ead, medeiros wmb, dos santos jpm, de sousa jmm, da costa fb, pontes km, et al. evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. trends psychiatry psychother. 2024;46:e20210396. doi: https://doi.org/10.47626/2237-6089-2021-0396 montagner pss, medeiros w, da silva lcr, borges cn, brasil-neto j, de deus silva barbosa v, et al. individually tailored dosage regimen of full-spectrum cannabis extracts for autistic core and comorbid symptoms: a real-life report of multi-symptomatic benefits. front psychiatry. 2023;14:1210155. doi: https://doi.org/10.3389/fpsyt.2023.1210155 schnapp a, harel m, cayam-rand d, cassuto h, polyansky l, aran a. a placebo-controlled trial of cannabinoid treatment for disruptive behavior in children and adolescents with autism spectrum disorder: effects on sleep parameters as measured by the cshq. biomedicines. 2022;10(7):1685. doi: https://doi.org/10.3390/biomedicines10071685 stolar o, hazan a, vissoker re, kishk ia, barchel d, lezinger m, et al. medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: an interim analysis of biochemical safety. front pharmacol. 2022;13:977484. doi: https://doi.org/10.3389/fphar.2022.977484 krebs mo, kebir o, jay tm. exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders. eur j pain. 2019;23(7):1225-1233. doi: https://doi.org/10.1002/ejp.1377 berry-kravis e, hagerman r, budimirovic d, erickson c, heussler h, tartaglia n, et al. a randomized, controlled trial of zyn002 cannabidiol transdermal gel in children and adolescents with fragile x syndrome (connect-fx). j neurodev disord. 2022;14(1):56. doi: https://doi.org/10.1186/s11689-022-09466-6 epidiolex ® (package insert). carlsbad, ca, usa: greenwich biosciences inc. 2018. thiele ea, marsh ed, french ja, mazurkiewicz-beldzinska m, benbadis sr, joshi c, et al. gwpcare4 study group. cannabidiol in patients with seizures associated with lennox-gastaut syndrome (gwpcare4): a randomised, double-blind, placebo-controlled phase 3 trial. lancet. 2018;391(10125):1085-96. doi: https://doi.org/10.1016/s0140-6736(18)30136-3 devinsky o, cross jh, laux l, marsh e, miller i, nabbout r, et al. cannabidiol in dravet syndrome study group. trial of cannabidiol for drug-resistant seizures in the dravet syndrome. n engl j med. 2017;376(21):2011-20. doi: https://doi.org/10.1056/nejmoa1611618 thiele ea, bebin em, bhathal h, jansen fe, kotulska k, lawson ja, et al. gwpcare6 study group. add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial. jama neurol. 2021;78(3):285-92. doi: https://doi.org/10.1001/jamaneurol.2020.4607 aman mg, singh nn. aberrant behavior checklist-2nd edition (abc-2). east aurora, ny, usa: slosson educational publications, inc. 1985. doi: https://doi.org/10.1037/t10453-000 roid hg, pomplun m. the stanford-binet intelligence scales. new york, ny, usa: the guilford press. 2012. sparrow ss, balla da, cicchetti dv. vineland adaptive behavior scales-third edition. san antonio, tx, usa: pearson. 2016. esbensen aj, rojahn j, aman mg, ruedrich s. anxiety, depression and mood scale (adams). columbus, ohio, usa: nisonger center. 2003. doi: https://doi.org/10.1037/t10454-000 butter e, mulick j. the ohio autism clinical impressions scale (oacis). columbus, oh, usa: children's research institute. 2006. constantino j. (srs™) social responsiveness scale-second edition. torrance, ca, usa: western psychological services. 2012. krug d, arick j, almond p. autism screening instrument for educational planning-third edition. austin, tx, usa: proed. 2008. bodfish jw, symons fw, parker de, lewis mh. the repetitive behavior scale-revised. dubuque, ia, usa: apa psyc tests. 2000. doi: https://doi.org/10.1037/t17338-000 malow ba, connolly hv, weiss sk, halbower a, goldman s, hyman sl, et al. the pediatric sleep clinical global impressions scale-a new tool to measure pediatric insomnia in autism spectrum disorders. j dev behav pediatr. 2016;37(5):370-6. doi: https://doi.org/10.1097/dbp.0000000000000307 gioia ga, isquith pk, guy sc, kenworthy l. behavior rating inventory of executive function®, second edition (brief®2). lutz, fl, usa: par inc. 2015. doi: https://doi.org/10.1037/t79467-000 leadbitter k, aldred c, mcconachie h, le couteur a, kapadia d, charman t, et al. pact consortium. the autism family experience questionnaire (afeq): an ecologically-valid, parent-nominated measure of family experience, quality of life and prioritised outcomes for early intervention. j autism dev disord. 2018;48(4):1052-62. doi: https://doi.org/10.1007/s10803-017-3350-7 forrest cb, ravens-sieberer u, devine j, becker bd, teneralli r, moon j, et al. development and evaluation of the promis® pediatric positive affect item bank, child-report and parent-proxy editions. j happiness stud. 2018;19(3):699-718. doi: https://doi.org/10.1007/s10902-016-9843-9 salsman jm, lai js, hendrie hc, butt z, zill n, pilkonis pa, et al. assessing psychological well-being: self-report instruments for the nih toolbox. qual life res. 2014;23(1):205-15. doi: https://doi.org/10.1007/s11136-013-0452-3 varni jw. the pedsql. san diego, ca, usa: children’s hospital and health center. 1999. posner k, brent d, lucas c, gould m, stanley b, brown g, et al. columbia suicide severity scale (c-ssrs). new york, ny, usa: the research foundation for mental hygiene. 2008. curran hv, freeman tp, mokrysz c, lewis da, morgan cj, parsons lh. keep off the grass? cannabis, cognition and addiction. nat rev neurosci. 2016;17(5):293-306. doi: https://doi.org/10.1038/nrn.2016.28 aran a, cayam rand d. cannabinoid treatment for the symptoms of autism spectrum disorder. expert opin emerg drugs. 2024;29(1):65-79. doi: https://doi.org/10.1080/14728214.2024.2306290 downloads pdf published 2025-01-28 how to cite sannar, e. m., winter, j., franke, r. k., werner, e., rochowiak, r., romani, p. w., miller, o. s., semmler, n., bainbridge, j. l., natvig, c., mikluich-gilbertson, s. k., & tartaglia, n. r. (2025). cannabidiol for treatment of irritability and aggressive behavior in children and adolescents with autism spectrum disorder: background and methods of the cannabidiol study in children with autism spectrum disorder study. international journal of clinical trials , 12 (1), 29–37. https://doi.org/10.18203/2349-3259.ijct20250131 more citation formats acm acs apa abnt chicago harvard ieee mla turabian vancouver download citation endnote/zotero/mendeley (ris) bibtex issue vol. 12 no. 1 (2025): january-march 2025 section protocols make a submission make a submission information for readers for authors for librarians keywords function randomcolor() { var cores = ['#1f77b4', '#ff7f0e', '#2ca02c', '#d62728', '#9467bd', '#8c564b', '#e377c2', '#7f7f7f', '#bcbd22', '#17becf']; return cores[math.floor(math.random()*cores.length)]; } document.addeventlistener("domcontentloaded", function() { var keywords = [{"text":"clinical trials","size":26},{"text":"clinical trial","size":17},{"text":"pain","size":9},{"text":"risk based monitoring","size":8},{"text":"clinical research","size":8},{"text":"physical activity","size":8},{"text":"covid-19","size":8},{"text":"india","size":8},{"text":"fentanyl","size":8},{"text":"ropivacaine","size":6},{"text":"anxiety","size":6},{"text":"randomized controlled trial","size":6},{"text":"depression","size":6},{"text":"osteoarthritis","size":5},{"text":"stroke","size":5},{"text":"obesity","size":5},{"text":"safety","size":5},{"text":"nutrition","size":5},{"text":"diabetes","size":5},{"text":"protocol","size":5},{"text":"type 2 diabetes mellitus","size":5},{"text":"dexmedetomidine","size":5},{"text":"physiotherapy","size":5},{"text":"oncology","size":5},{"text":"cancer","size":4},{"text":"randomized clinical trials","size":4},{"text":"efficacy","size":4},{"text":"quality of life","size":4},{"text":"children","size":4},{"text":"blood pressure","size":4},{"text":"bupivacaine","size":4},{"text":"exercise","size":4},{"text":"adolescents","size":4},{"text":"chemotherapy","size":3},{"text":"vitamin k2","size":3},{"text":"ctri","size":3},{"text":"nicotine","size":3},{"text":"e-cigarette","size":3},{"text":"hiv","size":3},{"text":"hysterosalpingography","size":3},{"text":"epilepsy","size":3},{"text":"cardiovascular disease","size":3},{"text":"iron deficiency anemia","size":3},{"text":"patents","size":3},{"text":"primary care","size":3},{"text":"ischemic stroke","size":3},{"text":"pharmacokinetics","size":3},{"text":"thrombocytopenia","size":3},{"text":"smartphone","size":3},{"text":"good clinical practice","size":3}]; var totalweight = 0; var width = 300; var height = 200; var transitionduration = 200; var length_keywords = keywords.length; var layout = d3.layout.cloud(); layout.size([width, height]) .words(keywords) .fontsize(function(d) { return fontsize(+d.size); }) .on('end', draw); var svg = d3.select("#wordcloud").append("svg") .attr("viewbox", "0 0 " + width + " " + height) .attr("width", '100%'); function update() { var words = layout.words(); fontsize = d3.scalelinear().range([16, 34]); if (words.length) { fontsize.domain([+words[words.length - 1].size || 1, +words[0].size]); } } keywords.foreach(function(item,index){totalweight += item.size;}); update(); function draw(words, bounds) { var w = layout.size()[0], h = layout.size()[1]; scaling = bounds ? math.min( w / math.abs(bounds[1].x - w / 2), w / math.abs(bounds[0].x - w / 2), h / math.abs(bounds[1].y - h / 2), h / math.abs(bounds[0].y - h / 2), ) / 2 : 1; svg .append("g") .attr( "transform", "translate(" + [w >> 1, h >> 1] + ")scale(" + scaling + ")", ) .selectall("text") .data(words) .enter().append("text") .style("font-size", function(d) { return d.size + "px"; }) .style("font-family", 'serif') .style("fill", randomcolor) .style('cursor', 'pointer') .style('opacity', 0.7) .attr('class', 'keyword') .attr("text-anchor", "middle") .attr("transform", function(d) { return "translate(" + [d.x, d.y] + ")rotate(" + d.rotate + ")"; }) .text(function(d) { return d.text; }) .on("click", function(d, i){ window.location = "https://www.ijclinicaltrials.com/index.php/ijct/search?query=query_slug".replace(/query_slug/, encodeuricomponent(''+d.text+'')); }) .on("mouseover", function(d, i) { d3.select(this).transition() .duration(transitionduration) .style('font-size',function(d) { return (d.size + 3) + "px"; }) .style('opacity', 1); }) .on("mouseout", function(d, i) { d3.select(this).transition() .duration(transitionduration) .style('font-size',function(d) { return d.size + "px"; }) .style('opacity', 0.7); }) .on('resize', function() { update() }); } layout.start(); }); current issue international journal of clinical trials. copyright © 2025. print issn: 2349-3240 | online issn: 2349-3259 editor@ijclinicaltrials.com , medipeditor@gmail.com (function (w, d, s, l, i) { w[l] = w[l] || []; var f = d.getelementsbytagname(s)[0], j = d.createelement(s), dl = l != 'datalayer' ? '&l=' + l : ''; j.async = true; j.src = 'https://www.googletagmanager.com/gtag/js?id=' + i + dl; f.parentnode.insertbefore(j, f); function gtag(){datalayer.push(arguments)}; gtag('js', new date()); gtag('config', i); }) (window, document, 'script', 'datalayer', 'ua-130662560-4');## Methods
of the cannabidiol study in children with autism spectrum disorder study | international journal of clinical trials skip to main content skip to main navigation menu skip to site footer open menu international journal of clinical trials home about about the journal submissions editorial team privacy statement contact login register articles in press current archives author guidelines search home / archives / vol. 12 no. 1 (2025): january-march 2025 / protocols cannabidiol for treatment of irritability and aggressive behavior in children and adolescents with autism spectrum disorder: background and methods of the cannabidiol study in children with autism spectrum disorder study authors elise m. sannar pediatric mental health institute, children’s hospital colorado, aurora, colorado, usa joan winter pediatric mental health institute, children’s hospital colorado, aurora, colorado, usa ronda k. franke department of pediatrics, children’s hospital colorado, aurora, colorado, usa emily werner department of pediatrics, children’s hospital colorado, aurora, colorado, usa rebecca rochowiak neuroscience institute, children’s hospital colorado, aurora, colorado, usa patrick w. romani pediatric mental health institute, children’s hospital colorado, aurora, colorado, usa owen s. miller department of clinical pharmacy, skaggs school of pharmacy, aurora, colorado, usa nicole semmler department of clinical pharmacy, skaggs school of pharmacy, aurora, colorado, usa jacquelyn l. bainbridge department of clinical pharmacy, skaggs school of pharmacy, aurora, colorado, usa crystal natvig department of psychiatry, university of colorado school of medicine, aurora, colorado, usa susan k. mikluich-gilbertson department of psychiatry, university of colorado school of medicine, aurora, colorado, usa nicole r. tartaglia department of pediatrics, children’s hospital colorado, aurora, colorado, usa doi: https://doi.org/10.18203/2349-3259.ijct20250131 keywords: autism spectrum disorder, cannabidiol, medication, clinical trial abstract background: autism spectrum disorder (asd) is a neurodevelopmental disorder commonly associated with behavioral challenges. there are few evidence based pharmacological interventions available for the treatment of behavioral symptoms associated with asd. cannabidiol (cbd), the non-intoxicating component of cannabis, has known neuroprotective, antiepileptic, anxiolytic, and antipsychotic effects and may be useful in treating the behavioral symptoms of asd. methods: we describe the research methods of a 27-week randomized placebo-controlled crossover trial to evaluate the safety and efficacy of oral cbd for the treatment of irritability and aggression associated with asd, as measured by the irritability subscale of the aberrant behavior checklist-2 nd edition (abc-2) in children and adolescents. conclusions: there is significant need for clinical research exploring alternative medications for the treatment of behavioral symptoms of asd. upcoming results from this trial will help answer the question of whether cbd may be a useful intervention in the management of asd. clinical trial registry: nct04520685. metrics metrics loading ... window.onload = function () { var options = { paperbuzzstatsjson: json.parse('{\"altmetrics_sources\":[{\"events\":null,\"events_count\":265,\"events_count_by_day\":[{\"count\":1,\"date\":\"2025-01-28\"},{\"count\":4,\"date\":\"2025-01-29\"},{\"count\":3,\"date\":\"2025-02-01\"},{\"count\":2,\"date\":\"2025-02-02\"},{\"count\":3,\"date\":\"2025-02-03\"},{\"count\":2,\"date\":\"2025-02-04\"},{\"count\":2,\"date\":\"2025-02-05\"},{\"count\":1,\"date\":\"2025-02-07\"},{\"count\":1,\"date\":\"2025-02-08\"},{\"count\":1,\"date\":\"2025-02-10\"},{\"count\":1,\"date\":\"2025-02-11\"},{\"count\":2,\"date\":\"2025-02-12\"},{\"count\":1,\"date\":\"2025-02-14\"},{\"count\":1,\"date\":\"2025-02-17\"},{\"count\":3,\"date\":\"2025-02-18\"},{\"count\":1,\"date\":\"2025-02-19\"},{\"count\":6,\"date\":\"2025-02-20\"},{\"count\":2,\"date\":\"2025-02-21\"},{\"count\":1,\"date\":\"2025-02-22\"},{\"count\":1,\"date\":\"2025-02-23\"},{\"count\":1,\"date\":\"2025-02-24\"},{\"count\":2,\"date\":\"2025-02-25\"},{\"count\":6,\"date\":\"2025-02-26\"}],\"events_count_by_month\":[{\"count\":5,\"date\":\"2025-01\"},{\"count\":45,\"date\":\"2025-02\"},{\"count\":32,\"date\":\"2025-03\"},{\"count\":37,\"date\":\"2025-04\"},{\"count\":26,\"date\":\"2025-05\"},{\"count\":23,\"date\":\"2025-06\"},{\"count\":19,\"date\":\"2025-07\"},{\"count\":24,\"date\":\"2025-08\"},{\"count\":24,\"date\":\"2025-09\"},{\"count\":30,\"date\":\"2025-10\"}],\"events_count_by_year\":[{\"count\":265,\"date\":null}],\"source\":{\"display_name\":\"pdf views\"},\"source_id\":\"pdf\"}]}'), minitemstoshowgraph: { mineventsforyearly: 10, mineventsformonthly: 10, mineventsfordaily: 6, minyearsforyearly: 3, minmonthsformonthly: 2, mindaysfordaily: 1 //first 30 days only }, graphheight: 150, graphwidth: 300, showtitle: false, showmini: false, published_date: [2025, 1, 28], } var paperbuzzviz = undefined; paperbuzzviz = new paperbuzzviz(options); paperbuzzviz.initviz(); } references american psychiatric association. diagnostic and statistical manual of mental disorders (5th ed.). washington, dc, usa: american psychiatric publishing. 2013. doi: https://doi.org/10.1176/appi.books.9780890425596 fombonne e, croen la, bulkley je, varga am, daida yg, hatch ba, et al. emotional and behavioral problems in youth with autism: high prevalence and impact on functioning. j dev behav pediatr. 2022;43(3):140-8. doi: https://doi.org/10.1097/dbp.0000000000001028 maenner mj, warren z, williams ar, amoakohene e, bakian av, bilder da, et al. prevalence and characteristics of autism spectrum disorder among children aged 8 years-autism and developmental disabilities monitoring network, 11 sites, united states, 2020. mmwr surveill summ. 2023;72(2):1-14. doi: https://doi.org/10.15585/mmwr.ss7202a1 owen r, sikich l, marcus rn, corey-lisle p, manos g, mcquade rd, et al. aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. pediatrics. 2009;124(6):1533-40. doi: https://doi.org/10.1542/peds.2008-3782 mccracken jt, mcgough j, shah b, cronin p, hong d, aman mg, et al. research units on pediatric psychopharmacology autism network. risperidone in children with autism and serious behavioral problems. n engl j med. 2002;347(5):314-21. doi: https://doi.org/10.1056/nejmoa013171 jobski k, höfer j, hoffmann f, bachmann c. use of psychotropic drugs in patients with autism spectrum disorders: a systematic review. acta psychiatr scand. 2017;135(1):8-28. doi: https://doi.org/10.1111/acps.12644 zou m, li d, li l, wu l, sun c. role of the endocannabinoid system in neurological disorders. int j dev neurosci. 2019;76:95-102. doi: https://doi.org/10.1016/j.ijdevneu.2019.03.002 campos ac, fogaça mv, scarante ff, joca srl, sales aj, gomes fv, et al. plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders. front pharmacol. 2017;8:269. doi: https://doi.org/10.3389/fphar.2017.00269 zamberletti e, gabaglio m, parolaro d. the endocannabinoid system and autism spectrum disorders: insights from animal models. int j mol sci. 2017;18(9):1916. doi: https://doi.org/10.3390/ijms18091916 silva junior ead, medeiros wmb, dos santos jpm, de sousa jmm, da costa fb, pontes km, et al. evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. trends psychiatry psychother. 2024;46:e20210396. doi: https://doi.org/10.47626/2237-6089-2021-0396 montagner pss, medeiros w, da silva lcr, borges cn, brasil-neto j, de deus silva barbosa v, et al. individually tailored dosage regimen of full-spectrum cannabis extracts for autistic core and comorbid symptoms: a real-life report of multi-symptomatic benefits. front psychiatry. 2023;14:1210155. doi: https://doi.org/10.3389/fpsyt.2023.1210155 schnapp a, harel m, cayam-rand d, cassuto h, polyansky l, aran a. a placebo-controlled trial of cannabinoid treatment for disruptive behavior in children and adolescents with autism spectrum disorder: effects on sleep parameters as measured by the cshq. biomedicines. 2022;10(7):1685. doi: https://doi.org/10.3390/biomedicines10071685 stolar o, hazan a, vissoker re, kishk ia, barchel d, lezinger m, et al. medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: an interim analysis of biochemical safety. front pharmacol. 2022;13:977484. doi: https://doi.org/10.3389/fphar.2022.977484 krebs mo, kebir o, jay tm. exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders. eur j pain. 2019;23(7):1225-1233. doi: https://doi.org/10.1002/ejp.1377 berry-kravis e, hagerman r, budimirovic d, erickson c, heussler h, tartaglia n, et al. a randomized, controlled trial of zyn002 cannabidiol transdermal gel in children and adolescents with fragile x syndrome (connect-fx). j neurodev disord. 2022;14(1):56. doi: https://doi.org/10.1186/s11689-022-09466-6 epidiolex ® (package insert). carlsbad, ca, usa: greenwich biosciences inc. 2018. thiele ea, marsh ed, french ja, mazurkiewicz-beldzinska m, benbadis sr, joshi c, et al. gwpcare4 study group. cannabidiol in patients with seizures associated with lennox-gastaut syndrome (gwpcare4): a randomised, double-blind, placebo-controlled phase 3 trial. lancet. 2018;391(10125):1085-96. doi: https://doi.org/10.1016/s0140-6736(18)30136-3 devinsky o, cross jh, laux l, marsh e, miller i, nabbout r, et al. cannabidiol in dravet syndrome study group. trial of cannabidiol for drug-resistant seizures in the dravet syndrome. n engl j med. 2017;376(21):2011-20. doi: https://doi.org/10.1056/nejmoa1611618 thiele ea, bebin em, bhathal h, jansen fe, kotulska k, lawson ja, et al. gwpcare6 study group. add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial. jama neurol. 2021;78(3):285-92. doi: https://doi.org/10.1001/jamaneurol.2020.4607 aman mg, singh nn. aberrant behavior checklist-2nd edition (abc-2). east aurora, ny, usa: slosson educational publications, inc. 1985. doi: https://doi.org/10.1037/t10453-000 roid hg, pomplun m. the stanford-binet intelligence scales. new york, ny, usa: the guilford press. 2012. sparrow ss, balla da, cicchetti dv. vineland adaptive behavior scales-third edition. san antonio, tx, usa: pearson. 2016. esbensen aj, rojahn j, aman mg, ruedrich s. anxiety, depression and mood scale (adams). columbus, ohio, usa: nisonger center. 2003. doi: https://doi.org/10.1037/t10454-000 butter e, mulick j. the ohio autism clinical impressions scale (oacis). columbus, oh, usa: children's research institute. 2006. constantino j. (srs™) social responsiveness scale-second edition. torrance, ca, usa: western psychological services. 2012. krug d, arick j, almond p. autism screening instrument for educational planning-third edition. austin, tx, usa: proed. 2008. bodfish jw, symons fw, parker de, lewis mh. the repetitive behavior scale-revised. dubuque, ia, usa: apa psyc tests. 2000. doi: https://doi.org/10.1037/t17338-000 malow ba, connolly hv, weiss sk, halbower a, goldman s, hyman sl, et al. the pediatric sleep clinical global impressions scale-a new tool to measure pediatric insomnia in autism spectrum disorders. j dev behav pediatr. 2016;37(5):370-6. doi: https://doi.org/10.1097/dbp.0000000000000307 gioia ga, isquith pk, guy sc, kenworthy l. behavior rating inventory of executive function®, second edition (brief®2). lutz, fl, usa: par inc. 2015. doi: https://doi.org/10.1037/t79467-000 leadbitter k, aldred c, mcconachie h, le couteur a, kapadia d, charman t, et al. pact consortium. the autism family experience questionnaire (afeq): an ecologically-valid, parent-nominated measure of family experience, quality of life and prioritised outcomes for early intervention. j autism dev disord. 2018;48(4):1052-62. doi: https://doi.org/10.1007/s10803-017-3350-7 forrest cb, ravens-sieberer u, devine j, becker bd, teneralli r, moon j, et al. development and evaluation of the promis® pediatric positive affect item bank, child-report and parent-proxy editions. j happiness stud. 2018;19(3):699-718. doi: https://doi.org/10.1007/s10902-016-9843-9 salsman jm, lai js, hendrie hc, butt z, zill n, pilkonis pa, et al. assessing psychological well-being: self-report instruments for the nih toolbox. qual life res. 2014;23(1):205-15. doi: https://doi.org/10.1007/s11136-013-0452-3 varni jw. the pedsql. san diego, ca, usa: children’s hospital and health center. 1999. posner k, brent d, lucas c, gould m, stanley b, brown g, et al. columbia suicide severity scale (c-ssrs). new york, ny, usa: the research foundation for mental hygiene. 2008. curran hv, freeman tp, mokrysz c, lewis da, morgan cj, parsons lh. keep off the grass? cannabis, cognition and addiction. nat rev neurosci. 2016;17(5):293-306. doi: https://doi.org/10.1038/nrn.2016.28 aran a, cayam rand d. cannabinoid treatment for the symptoms of autism spectrum disorder. expert opin emerg drugs. 2024;29(1):65-79. doi: https://doi.org/10.1080/14728214.2024.2306290 downloads pdf published 2025-01-28 how to cite sannar, e. m., winter, j., franke, r. k., werner, e., rochowiak, r., romani, p. w., miller, o. s., semmler, n., bainbridge, j. l., natvig, c., mikluich-gilbertson, s. k., & tartaglia, n. r. (2025). cannabidiol for treatment of irritability and aggressive behavior in children and adolescents with autism spectrum disorder: background and methods of the cannabidiol study in children with autism spectrum disorder study. international journal of clinical trials , 12 (1), 29–37. https://doi.org/10.18203/2349-3259.ijct20250131 more citation formats acm acs apa abnt chicago harvard ieee mla turabian vancouver download citation endnote/zotero/mendeley (ris) bibtex issue vol. 12 no. 1 (2025): january-march 2025 section protocols make a submission make a submission information for readers for authors for librarians keywords function randomcolor() { var cores = ['#1f77b4', '#ff7f0e', '#2ca02c', '#d62728', '#9467bd', '#8c564b', '#e377c2', '#7f7f7f', '#bcbd22', '#17becf']; return cores[math.floor(math.random()*cores.length)]; } document.addeventlistener("domcontentloaded", function() { var keywords = [{"text":"clinical trials","size":26},{"text":"clinical trial","size":17},{"text":"pain","size":9},{"text":"risk based monitoring","size":8},{"text":"clinical research","size":8},{"text":"physical activity","size":8},{"text":"covid-19","size":8},{"text":"india","size":8},{"text":"fentanyl","size":8},{"text":"ropivacaine","size":6},{"text":"anxiety","size":6},{"text":"randomized controlled trial","size":6},{"text":"depression","size":6},{"text":"osteoarthritis","size":5},{"text":"stroke","size":5},{"text":"obesity","size":5},{"text":"safety","size":5},{"text":"nutrition","size":5},{"text":"diabetes","size":5},{"text":"protocol","size":5},{"text":"type 2 diabetes mellitus","size":5},{"text":"dexmedetomidine","size":5},{"text":"physiotherapy","size":5},{"text":"oncology","size":5},{"text":"cancer","size":4},{"text":"randomized clinical trials","size":4},{"text":"efficacy","size":4},{"text":"quality of life","size":4},{"text":"children","size":4},{"text":"blood pressure","size":4},{"text":"bupivacaine","size":4},{"text":"exercise","size":4},{"text":"adolescents","size":4},{"text":"chemotherapy","size":3},{"text":"vitamin k2","size":3},{"text":"ctri","size":3},{"text":"nicotine","size":3},{"text":"e-cigarette","size":3},{"text":"hiv","size":3},{"text":"hysterosalpingography","size":3},{"text":"epilepsy","size":3},{"text":"cardiovascular disease","size":3},{"text":"iron deficiency anemia","size":3},{"text":"patents","size":3},{"text":"primary care","size":3},{"text":"ischemic stroke","size":3},{"text":"pharmacokinetics","size":3},{"text":"thrombocytopenia","size":3},{"text":"smartphone","size":3},{"text":"good clinical practice","size":3}]; var totalweight = 0; var width = 300; var height = 200; var transitionduration = 200; var length_keywords = keywords.length; var layout = d3.layout.cloud(); layout.size([width, height]) .words(keywords) .fontsize(function(d) { return fontsize(+d.size); }) .on('end', draw); var svg = d3.select("#wordcloud").append("svg") .attr("viewbox", "0 0 " + width + " " + height) .attr("width", '100%'); function update() { var words = layout.words(); fontsize = d3.scalelinear().range([16, 34]); if (words.length) { fontsize.domain([+words[words.length - 1].size || 1, +words[0].size]); } } keywords.foreach(function(item,index){totalweight += item.size;}); update(); function draw(words, bounds) { var w = layout.size()[0], h = layout.size()[1]; scaling = bounds ? math.min( w / math.abs(bounds[1].x - w / 2), w / math.abs(bounds[0].x - w / 2), h / math.abs(bounds[1].y - h / 2), h / math.abs(bounds[0].y - h / 2), ) / 2 : 1; svg .append("g") .attr( "transform", "translate(" + [w >> 1, h >> 1] + ")scale(" + scaling + ")", ) .selectall("text") .data(words) .enter().append("text") .style("font-size", function(d) { return d.size + "px"; }) .style("font-family", 'serif') .style("fill", randomcolor) .style('cursor', 'pointer') .style('opacity', 0.7) .attr('class', 'keyword') .attr("text-anchor", "middle") .attr("transform", function(d) { return "translate(" + [d.x, d.y] + ")rotate(" + d.rotate + ")"; }) .text(function(d) { return d.text; }) .on("click", function(d, i){ window.location = "https://www.ijclinicaltrials.com/index.php/ijct/search?query=query_slug".replace(/query_slug/, encodeuricomponent(''+d.text+'')); }) .on("mouseover", function(d, i) { d3.select(this).transition() .duration(transitionduration) .style('font-size',function(d) { return (d.size + 3) + "px"; }) .style('opacity', 1); }) .on("mouseout", function(d, i) { d3.select(this).transition() .duration(transitionduration) .style('font-size',function(d) { return d.size + "px"; }) .style('opacity', 0.7); }) .on('resize', function() { update() }); } layout.start(); }); current issue international journal of clinical trials. copyright © 2025. print issn: 2349-3240 | online issn: 2349-3259 editor@ijclinicaltrials.com , medipeditor@gmail.com (function (w, d, s, l, i) { w[l] = w[l] || []; var f = d.getelementsbytagname(s)[0], j = d.createelement(s), dl = l != 'datalayer' ? '&l=' + l : ''; j.async = true; j.src = 'https://www.googletagmanager.com/gtag/js?id=' + i + dl; f.parentnode.insertbefore(j, f); function gtag(){datalayer.push(arguments)}; gtag('js', new date()); gtag('config', i); }) (window, document, 'script', 'datalayer', 'ua-130662560-4');## Results
from this trial will help answer the question of whether cbd may be a useful intervention in the management of asd. clinical trial registry: nct04520685. metrics metrics loading ... window.onload = function () { var options = { paperbuzzstatsjson: json.parse('{\"altmetrics_sources\":[{\"events\":null,\"events_count\":265,\"events_count_by_day\":[{\"count\":1,\"date\":\"2025-01-28\"},{\"count\":4,\"date\":\"2025-01-29\"},{\"count\":3,\"date\":\"2025-02-01\"},{\"count\":2,\"date\":\"2025-02-02\"},{\"count\":3,\"date\":\"2025-02-03\"},{\"count\":2,\"date\":\"2025-02-04\"},{\"count\":2,\"date\":\"2025-02-05\"},{\"count\":1,\"date\":\"2025-02-07\"},{\"count\":1,\"date\":\"2025-02-08\"},{\"count\":1,\"date\":\"2025-02-10\"},{\"count\":1,\"date\":\"2025-02-11\"},{\"count\":2,\"date\":\"2025-02-12\"},{\"count\":1,\"date\":\"2025-02-14\"},{\"count\":1,\"date\":\"2025-02-17\"},{\"count\":3,\"date\":\"2025-02-18\"},{\"count\":1,\"date\":\"2025-02-19\"},{\"count\":6,\"date\":\"2025-02-20\"},{\"count\":2,\"date\":\"2025-02-21\"},{\"count\":1,\"date\":\"2025-02-22\"},{\"count\":1,\"date\":\"2025-02-23\"},{\"count\":1,\"date\":\"2025-02-24\"},{\"count\":2,\"date\":\"2025-02-25\"},{\"count\":6,\"date\":\"2025-02-26\"}],\"events_count_by_month\":[{\"count\":5,\"date\":\"2025-01\"},{\"count\":45,\"date\":\"2025-02\"},{\"count\":32,\"date\":\"2025-03\"},{\"count\":37,\"date\":\"2025-04\"},{\"count\":26,\"date\":\"2025-05\"},{\"count\":23,\"date\":\"2025-06\"},{\"count\":19,\"date\":\"2025-07\"},{\"count\":24,\"date\":\"2025-08\"},{\"count\":24,\"date\":\"2025-09\"},{\"count\":30,\"date\":\"2025-10\"}],\"events_count_by_year\":[{\"count\":265,\"date\":null}],\"source\":{\"display_name\":\"pdf views\"},\"source_id\":\"pdf\"}]}'), minitemstoshowgraph: { mineventsforyearly: 10, mineventsformonthly: 10, mineventsfordaily: 6, minyearsforyearly: 3, minmonthsformonthly: 2, mindaysfordaily: 1 //first 30 days only }, graphheight: 150, graphwidth: 300, showtitle: false, showmini: false, published_date: [2025, 1, 28], } var paperbuzzviz = undefined; paperbuzzviz = new paperbuzzviz(options); paperbuzzviz.initviz(); } references american psychiatric association. diagnostic and statistical manual of mental disorders (5th ed.). washington, dc, usa: american psychiatric publishing. 2013. doi: https://doi.org/10.1176/appi.books.9780890425596 fombonne e, croen la, bulkley je, varga am, daida yg, hatch ba, et al. emotional and behavioral problems in youth with autism: high prevalence and impact on functioning. j dev behav pediatr. 2022;43(3):140-8. doi: https://doi.org/10.1097/dbp.0000000000001028 maenner mj, warren z, williams ar, amoakohene e, bakian av, bilder da, et al. prevalence and characteristics of autism spectrum disorder among children aged 8 years-autism and developmental disabilities monitoring network, 11 sites, united states, 2020. mmwr surveill summ. 2023;72(2):1-14. doi: https://doi.org/10.15585/mmwr.ss7202a1 owen r, sikich l, marcus rn, corey-lisle p, manos g, mcquade rd, et al. aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. pediatrics. 2009;124(6):1533-40. doi: https://doi.org/10.1542/peds.2008-3782 mccracken jt, mcgough j, shah b, cronin p, hong d, aman mg, et al. research units on pediatric psychopharmacology autism network. risperidone in children with autism and serious behavioral problems. n engl j med. 2002;347(5):314-21. doi: https://doi.org/10.1056/nejmoa013171 jobski k, höfer j, hoffmann f, bachmann c. use of psychotropic drugs in patients with autism spectrum disorders: a systematic review. acta psychiatr scand. 2017;135(1):8-28. doi: https://doi.org/10.1111/acps.12644 zou m, li d, li l, wu l, sun c. role of the endocannabinoid system in neurological disorders. int j dev neurosci. 2019;76:95-102. doi: https://doi.org/10.1016/j.ijdevneu.2019.03.002 campos ac, fogaça mv, scarante ff, joca srl, sales aj, gomes fv, et al. plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders. front pharmacol. 2017;8:269. doi: https://doi.org/10.3389/fphar.2017.00269 zamberletti e, gabaglio m, parolaro d. the endocannabinoid system and autism spectrum disorders: insights from animal models. int j mol sci. 2017;18(9):1916. doi: https://doi.org/10.3390/ijms18091916 silva junior ead, medeiros wmb, dos santos jpm, de sousa jmm, da costa fb, pontes km, et al. evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. trends psychiatry psychother. 2024;46:e20210396. doi: https://doi.org/10.47626/2237-6089-2021-0396 montagner pss, medeiros w, da silva lcr, borges cn, brasil-neto j, de deus silva barbosa v, et al. individually tailored dosage regimen of full-spectrum cannabis extracts for autistic core and comorbid symptoms: a real-life report of multi-symptomatic benefits. front psychiatry. 2023;14:1210155. doi: https://doi.org/10.3389/fpsyt.2023.1210155 schnapp a, harel m, cayam-rand d, cassuto h, polyansky l, aran a. a placebo-controlled trial of cannabinoid treatment for disruptive behavior in children and adolescents with autism spectrum disorder: effects on sleep parameters as measured by the cshq. biomedicines. 2022;10(7):1685. doi: https://doi.org/10.3390/biomedicines10071685 stolar o, hazan a, vissoker re, kishk ia, barchel d, lezinger m, et al. medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: an interim analysis of biochemical safety. front pharmacol. 2022;13:977484. doi: https://doi.org/10.3389/fphar.2022.977484 krebs mo, kebir o, jay tm. exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders. eur j pain. 2019;23(7):1225-1233. doi: https://doi.org/10.1002/ejp.1377 berry-kravis e, hagerman r, budimirovic d, erickson c, heussler h, tartaglia n, et al. a randomized, controlled trial of zyn002 cannabidiol transdermal gel in children and adolescents with fragile x syndrome (connect-fx). j neurodev disord. 2022;14(1):56. doi: https://doi.org/10.1186/s11689-022-09466-6 epidiolex ® (package insert). carlsbad, ca, usa: greenwich biosciences inc. 2018. thiele ea, marsh ed, french ja, mazurkiewicz-beldzinska m, benbadis sr, joshi c, et al. gwpcare4 study group. cannabidiol in patients with seizures associated with lennox-gastaut syndrome (gwpcare4): a randomised, double-blind, placebo-controlled phase 3 trial. lancet. 2018;391(10125):1085-96. doi: https://doi.org/10.1016/s0140-6736(18)30136-3 devinsky o, cross jh, laux l, marsh e, miller i, nabbout r, et al. cannabidiol in dravet syndrome study group. trial of cannabidiol for drug-resistant seizures in the dravet syndrome. n engl j med. 2017;376(21):2011-20. doi: https://doi.org/10.1056/nejmoa1611618 thiele ea, bebin em, bhathal h, jansen fe, kotulska k, lawson ja, et al. gwpcare6 study group. add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial. jama neurol. 2021;78(3):285-92. doi: https://doi.org/10.1001/jamaneurol.2020.4607 aman mg, singh nn. aberrant behavior checklist-2nd edition (abc-2). east aurora, ny, usa: slosson educational publications, inc. 1985. doi: https://doi.org/10.1037/t10453-000 roid hg, pomplun m. the stanford-binet intelligence scales. new york, ny, usa: the guilford press. 2012. sparrow ss, balla da, cicchetti dv. vineland adaptive behavior scales-third edition. san antonio, tx, usa: pearson. 2016. esbensen aj, rojahn j, aman mg, ruedrich s. anxiety, depression and mood scale (adams). columbus, ohio, usa: nisonger center. 2003. doi: https://doi.org/10.1037/t10454-000 butter e, mulick j. the ohio autism clinical impressions scale (oacis). columbus, oh, usa: children's research institute. 2006. constantino j. (srs™) social responsiveness scale-second edition. torrance, ca, usa: western psychological services. 2012. krug d, arick j, almond p. autism screening instrument for educational planning-third edition. austin, tx, usa: proed. 2008. bodfish jw, symons fw, parker de, lewis mh. the repetitive behavior scale-revised. dubuque, ia, usa: apa psyc tests. 2000. doi: https://doi.org/10.1037/t17338-000 malow ba, connolly hv, weiss sk, halbower a, goldman s, hyman sl, et al. the pediatric sleep clinical global impressions scale-a new tool to measure pediatric insomnia in autism spectrum disorders. j dev behav pediatr. 2016;37(5):370-6. doi: https://doi.org/10.1097/dbp.0000000000000307 gioia ga, isquith pk, guy sc, kenworthy l. behavior rating inventory of executive function®, second edition (brief®2). lutz, fl, usa: par inc. 2015. doi: https://doi.org/10.1037/t79467-000 leadbitter k, aldred c, mcconachie h, le couteur a, kapadia d, charman t, et al. pact consortium. the autism family experience questionnaire (afeq): an ecologically-valid, parent-nominated measure of family experience, quality of life and prioritised outcomes for early intervention. j autism dev disord. 2018;48(4):1052-62. doi: https://doi.org/10.1007/s10803-017-3350-7 forrest cb, ravens-sieberer u, devine j, becker bd, teneralli r, moon j, et al. development and evaluation of the promis® pediatric positive affect item bank, child-report and parent-proxy editions. j happiness stud. 2018;19(3):699-718. doi: https://doi.org/10.1007/s10902-016-9843-9 salsman jm, lai js, hendrie hc, butt z, zill n, pilkonis pa, et al. assessing psychological well-being: self-report instruments for the nih toolbox. qual life res. 2014;23(1):205-15. doi: https://doi.org/10.1007/s11136-013-0452-3 varni jw. the pedsql. san diego, ca, usa: children’s hospital and health center. 1999. posner k, brent d, lucas c, gould m, stanley b, brown g, et al. columbia suicide severity scale (c-ssrs). new york, ny, usa: the research foundation for mental hygiene. 2008. curran hv, freeman tp, mokrysz c, lewis da, morgan cj, parsons lh. keep off the grass? cannabis, cognition and addiction. nat rev neurosci. 2016;17(5):293-306. doi: https://doi.org/10.1038/nrn.2016.28 aran a, cayam rand d. cannabinoid treatment for the symptoms of autism spectrum disorder. expert opin emerg drugs. 2024;29(1):65-79. doi: https://doi.org/10.1080/14728214.2024.2306290 downloads pdf published 2025-01-28 how to cite sannar, e. m., winter, j., franke, r. k., werner, e., rochowiak, r., romani, p. w., miller, o. s., semmler, n., bainbridge, j. l., natvig, c., mikluich-gilbertson, s. k., & tartaglia, n. r. (2025). cannabidiol for treatment of irritability and aggressive behavior in children and adolescents with autism spectrum disorder: background and methods of the cannabidiol study in children with autism spectrum disorder study. international journal of clinical trials , 12 (1), 29–37. https://doi.org/10.18203/2349-3259.ijct20250131 more citation formats acm acs apa abnt chicago harvard ieee mla turabian vancouver download citation endnote/zotero/mendeley (ris) bibtex issue vol. 12 no. 1 (2025): january-march 2025 section protocols make a submission make a submission information for readers for authors for librarians keywords function randomcolor() { var cores = ['#1f77b4', '#ff7f0e', '#2ca02c', '#d62728', '#9467bd', '#8c564b', '#e377c2', '#7f7f7f', '#bcbd22', '#17becf']; return cores[math.floor(math.random()*cores.length)]; } document.addeventlistener("domcontentloaded", function() { var keywords = [{"text":"clinical trials","size":26},{"text":"clinical trial","size":17},{"text":"pain","size":9},{"text":"risk based monitoring","size":8},{"text":"clinical research","size":8},{"text":"physical activity","size":8},{"text":"covid-19","size":8},{"text":"india","size":8},{"text":"fentanyl","size":8},{"text":"ropivacaine","size":6},{"text":"anxiety","size":6},{"text":"randomized controlled trial","size":6},{"text":"depression","size":6},{"text":"osteoarthritis","size":5},{"text":"stroke","size":5},{"text":"obesity","size":5},{"text":"safety","size":5},{"text":"nutrition","size":5},{"text":"diabetes","size":5},{"text":"protocol","size":5},{"text":"type 2 diabetes mellitus","size":5},{"text":"dexmedetomidine","size":5},{"text":"physiotherapy","size":5},{"text":"oncology","size":5},{"text":"cancer","size":4},{"text":"randomized clinical trials","size":4},{"text":"efficacy","size":4},{"text":"quality of life","size":4},{"text":"children","size":4},{"text":"blood pressure","size":4},{"text":"bupivacaine","size":4},{"text":"exercise","size":4},{"text":"adolescents","size":4},{"text":"chemotherapy","size":3},{"text":"vitamin k2","size":3},{"text":"ctri","size":3},{"text":"nicotine","size":3},{"text":"e-cigarette","size":3},{"text":"hiv","size":3},{"text":"hysterosalpingography","size":3},{"text":"epilepsy","size":3},{"text":"cardiovascular disease","size":3},{"text":"iron deficiency anemia","size":3},{"text":"patents","size":3},{"text":"primary care","size":3},{"text":"ischemic stroke","size":3},{"text":"pharmacokinetics","size":3},{"text":"thrombocytopenia","size":3},{"text":"smartphone","size":3},{"text":"good clinical practice","size":3}]; var totalweight = 0; var width = 300; var height = 200; var transitionduration = 200; var length_keywords = keywords.length; var layout = d3.layout.cloud(); layout.size([width, height]) .words(keywords) .fontsize(function(d) { return fontsize(+d.size); }) .on('end', draw); var svg = d3.select("#wordcloud").append("svg") .attr("viewbox", "0 0 " + width + " " + height) .attr("width", '100%'); function update() { var words = layout.words(); fontsize = d3.scalelinear().range([16, 34]); if (words.length) { fontsize.domain([+words[words.length - 1].size || 1, +words[0].size]); } } keywords.foreach(function(item,index){totalweight += item.size;}); update(); function draw(words, bounds) { var w = layout.size()[0], h = layout.size()[1]; scaling = bounds ? math.min( w / math.abs(bounds[1].x - w / 2), w / math.abs(bounds[0].x - w / 2), h / math.abs(bounds[1].y - h / 2), h / math.abs(bounds[0].y - h / 2), ) / 2 : 1; svg .append("g") .attr( "transform", "translate(" + [w >> 1, h >> 1] + ")scale(" + scaling + ")", ) .selectall("text") .data(words) .enter().append("text") .style("font-size", function(d) { return d.size + "px"; }) .style("font-family", 'serif') .style("fill", randomcolor) .style('cursor', 'pointer') .style('opacity', 0.7) .attr('class', 'keyword') .attr("text-anchor", "middle") .attr("transform", function(d) { return "translate(" + [d.x, d.y] + ")rotate(" + d.rotate + ")"; }) .text(function(d) { return d.text; }) .on("click", function(d, i){ window.location = "https://www.ijclinicaltrials.com/index.php/ijct/search?query=query_slug".replace(/query_slug/, encodeuricomponent(''+d.text+'')); }) .on("mouseover", function(d, i) { d3.select(this).transition() .duration(transitionduration) .style('font-size',function(d) { return (d.size + 3) + "px"; }) .style('opacity', 1); }) .on("mouseout", function(d, i) { d3.select(this).transition() .duration(transitionduration) .style('font-size',function(d) { return d.size + "px"; }) .style('opacity', 0.7); }) .on('resize', function() { update() }); } layout.start(); }); current issue international journal of clinical trials. copyright © 2025. print issn: 2349-3240 | online issn: 2349-3259 editor@ijclinicaltrials.com , medipeditor@gmail.com (function (w, d, s, l, i) { w[l] = w[l] || []; var f = d.getelementsbytagname(s)[0], j = d.createelement(s), dl = l != 'datalayer' ? '&l=' + l : ''; j.async = true; j.src = 'https://www.googletagmanager.com/gtag/js?id=' + i + dl; f.parentnode.insertbefore(j, f); function gtag(){datalayer.push(arguments)}; gtag('js', new date()); gtag('config', i); }) (window, document, 'script', 'datalayer', 'ua-130662560-4');## Scraping Notes- Successfully scraped from DOI.org